Amoxicillin
drugOn this page
Also known as Amix 125Amix 250Amix 500AmopenAmoramAmoxicilinaAmoxicillin (anhydrous)Amoxicillin (as trihydrate)Amoxicillin anhydrousAmoxicillin component of augmentinAmoxicillin component of prevpacAmoxicillin component of taliciaAmoxicillin hydrateAmoxicillin pediatricAmoxicillin trihydrateAmoxicillineAmoxicillinum trihydricumAmoxident 250Amoxident 500
Summary
Amoxicillin (CHEMBL1082) is an approved small-molecule antibacterial drug (ATC J01CA04); indicated across 74 conditions including duodenal ulcer and urinary tract infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01CA04
- Indications: 74 conditions
- Clinical trials: 418
- Chemistry: 365.4 Da · C16H19N3O5S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1082 |
| Name | Amoxicillin |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 33613 |
| ChEBI | CHEBI:2676 |
| ATC | J01CA04 |
| Molecular formula | C16H19N3O5S |
| Molecular weight | 365.4 |
| InChIKey | LSQZJLSUYDQPKJ-NJBDSQKTSA-N |
SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
IUPAC name: (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
ChEBI definition: A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.
Pharmacological roles (ChEBI): antibacterial drug.
Also known as: Amix 125, Amix 250, Amix 500, Amopen, Amoram, Amoxicilina, Amoxicillin, Amoxicillin (anhydrous), Amoxicillin (as trihydrate), Amoxicillin anhydrous, Amoxicillin component of augmentin, Amoxicillin component of prevpac
Parent form; salt/anhydrous children: CHEMBL2105950
Patent coverage: 46,554 distinct patent families (113,048 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Lysine-specific demethylase 4E, Retinoic acid receptor gamma, Retinoic acid receptor beta, Beta-lactamase, Oxysterols receptor LXR-alpha, Oxysterols receptor LXR-beta, Nuclear receptor subfamily 1 group I member 3.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| NR1H2 | 5.39 | AC50 | 4100 | nM | CHEMBL_ACT_25202364 |
| RARG | 5.04 | AC50 | 9100 | nM | CHEMBL_ACT_25211923 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
74 indications (14 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| duodenal ulcer | 4 | MONDO:0005412 | EFO:0004607 |
| urinary tract infection | 4 | MONDO:0100338 | EFO:0003103 |
| otitis media | 4 | MONDO:0005441 | EFO:0004992 |
| sinusitis | 4 | MONDO:0005961 | EFO:0007486 |
| gonorrhea | 4 | MONDO:0004277 | DOID:7551 |
| pneumonia | 4 | MONDO:0005249 | EFO:0003106 |
| tonsillitis | 4 | MONDO:0001039 | HP:0011110 |
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| pharyngitis | 4 | MONDO:0002258 | MONDO:0002258 |
| respiratory tract infectious disorder | 4 | MONDO:0024355 | MONDO:0024355 |
| chronic bronchitis | 3 | MONDO:0005607 | EFO:0006505 |
| infectious disease | 3 | MONDO:0005550 | EFO:0005741 |
| periodontitis | 3 | MONDO:0005076 | EFO:0000649 |
| non-Hodgkin lymphoma | 3 | MONDO:0018908 | EFO:0005952 |
| suppurative otitis media | 3 | MONDO:0005975 | EFO:0007503 |
| Helicobacter pylori infectious disease | 3 | MONDO:0006781 | EFO:1000961 |
| alcoholic hepatitis | 3 | MONDO:0001505 | EFO:1001345 |
| dyspepsia | 3 | MONDO:0002268 | EFO:0008533 |
| pyelonephritis | 3 | MONDO:0006939 | EFO:1001141 |
| cholecystitis | 3 | MONDO:0002155 | HP:0001082 |
| endocarditis | 3 | MONDO:0005025 | MONDO:0000565 |
| neutropenia | 3 | MONDO:0001475 | MONDO:0001475 |
| gastritis | 3 | MONDO:0004966 | EFO:0000217 |
| gastric ulcer | 3 | MONDO:0001126 | EFO:0009454 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| influenza | 3 | MONDO:0005812 | EFO:0007328 |
| Plasmodium falciparum malaria | 3 | MONDO:0005920 | EFO:0007444 |
| allergic disease | 3 | MONDO:0005271 | MONDO:0005271 |
| cystitis | 3 | MONDO:0006032 | EFO:1000025 |
| alcoholic liver disease | 3 | MONDO:0043693 | EFO:0008573 |
| bronchitis | 3 | MONDO:0003781 | EFO:0009661 |
| Clostridium infectious disease | 3 | MONDO:0024388 | EFO:1000874 |
| MALT lymphoma | 2 | MONDO:0007650 | EFO:0000191 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| bacterial infectious disease with sepsis | 2 | MONDO:0005229 | EFO:0003033 |
| bacterial vaginosis | 2 | MONDO:0005316 | EFO:0003932 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| chlamydia trachomatis infectious disease | 2 | MONDO:0005701 | EFO:0007205 |
| pseudomyxoma peritonei | 2 | MONDO:0017048 | EFO:0007456 |
| pulmonary tuberculosis | 2 | MONDO:0006052 | EFO:1000049 |
| bacterial pneumonia | 2 | MONDO:0004652 | EFO:1001272 |
| periapical periodontitis | 2 | MONDO:0004508 | EFO:1001391 |
| ulcerative colitis | 2 | MONDO:0005101 | EFO:0000729 |
| mastitis | 2 | MONDO:0006849 | EFO:1001034 |
| Buruli ulcer disease | 2 | MONDO:0000327 | MONDO:0000327 |
| asthma | 2 | MONDO:0004979 | MONDO:0004979 |
| tuberculosis | 2 | MONDO:0018076 | MONDO:0018076 |
| periodontal disorder | 2 | MONDO:0002635 | MONDO:0002635 |
| obesity disorder | 1 | MONDO:0011122 | EFO:0001073 |
| morbid obesity | 1 | MONDO:0005139 | EFO:0001074 |
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| anaplastic astrocytoma | 1 | MONDO:0016684 | EFO:0002499 |
| central serous chorioretinopathy | 1 | MONDO:0018616 | EFO:0009784 |
| brain neoplasm | 1 | MONDO:0021211 | EFO:0003833 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
| tooth disorder | 0 | MONDO:0006999 | EFO:1001216 |
| diarrheal disease | 0 | MONDO:0001673 | HP:0002014 |
| sclerosing cholangitis | 0 | MONDO:0018646 | EFO:0004268 |
16 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 418.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 170 |
| Not specified | 102 |
| PHASE3 | 69 |
| PHASE2 | 25 |
| PHASE1 | 21 |
| PHASE2/PHASE3 | 12 |
| EARLY_PHASE1 | 10 |
| PHASE1/PHASE2 | 9 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04047849 | PHASE4 | RECRUITING | Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA |
| NCT04552080 | PHASE4 | RECRUITING | The Effect of Systemic Antibiotics on Post-surgical Complications and Patient-centered Outcomes in Patients Undergoing Implant Surgery With Guided Bone Regeneration and Simultaneous Sinus Floor Elevation |
| NCT04728516 | PHASE4 | RECRUITING | The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients |
| NCT05061732 | PHASE4 | RECRUITING | Helicobacter Pylori Eradication and Follow-up |
| NCT05345457 | PHASE4 | RECRUITING | Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age |
| NCT05398679 | PHASE4 | RECRUITING | Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis |
| NCT05846399 | PHASE4 | RECRUITING | CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) |
| NCT06010719 | PHASE4 | RECRUITING | Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition |
| NCT06076304 | PHASE4 | RECRUITING | Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis |
| NCT06168214 | PHASE4 | RECRUITING | Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication |
| NCT06378502 | PHASE4 | NOT_YET_RECRUITING | The Effect of Different Antibiotic Protocols on Peri-implant Tissue Health |
| NCT06396078 | PHASE4 | RECRUITING | Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) |
| NCT06412640 | PHASE4 | NOT_YET_RECRUITING | Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori |
| NCT06451913 | PHASE4 | RECRUITING | Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis)) |
| NCT06494072 | PHASE4 | RECRUITING | Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP |
| NCT06523764 | PHASE4 | ACTIVE_NOT_RECRUITING | Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment |
| NCT06561698 | PHASE4 | RECRUITING | High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection |
| NCT06709196 | PHASE4 | RECRUITING | Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis |
| NCT06723197 | PHASE4 | RECRUITING | Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication |
| NCT07040839 | PHASE4 | NOT_YET_RECRUITING | Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection |
| NCT07068607 | PHASE4 | RECRUITING | Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial |
| NCT07242443 | PHASE4 | NOT_YET_RECRUITING | Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori） |
| NCT07275580 | PHASE4 | NOT_YET_RECRUITING | Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases |
| NCT07457385 | PHASE4 | NOT_YET_RECRUITING | Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates |
| NCT00001658 | PHASE4 | COMPLETED | Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections |
| NCT00147914 | PHASE4 | COMPLETED | Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life |
| NCT00343135 | PHASE4 | COMPLETED | AUGMENTIN 1gm In Skin And Soft Tissue Infection |
| NCT00367120 | PHASE4 | COMPLETED | Zmax Compared to Augmentin in Sinusitis |
| NCT00377403 | PHASE4 | COMPLETED | Treatment of Acute Sinusitis |
| NCT00467571 | PHASE4 | COMPLETED | Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura |
| NCT00493038 | PHASE4 | TERMINATED | Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis |
| NCT00495586 | PHASE4 | COMPLETED | Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease |
| NCT00539149 | PHASE4 | COMPLETED | Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children |
| NCT00644891 | PHASE4 | COMPLETED | Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications |
| NCT00644943 | PHASE4 | COMPLETED | A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media |
| NCT00645125 | PHASE4 | COMPLETED | A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications |
| NCT00665873 | PHASE4 | COMPLETED | Antibiotic Therapy is Not Necessary to Implant Totally Implantable Venous Access Devices: Randomized Prospective Study |
| NCT00707369 | PHASE4 | COMPLETED | Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization |
| NCT00764062 | PHASE4 | TERMINATED | Amoxicillin Susceptibility of Oral Streptococci After a 3-Day or a 7-Day Amoxicillin Therapy |
| NCT00799838 | PHASE4 | TERMINATED | Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 41 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: duodenal ulcer, urinary tract infection, otitis media, sinusitis, gonorrhea, pneumonia, tonsillitis, bacterial infectious disease, pharyngitis, respiratory tract infectious disorder, chronic bronchitis, infectious disease, periodontitis, non-Hodgkin lymphoma, suppurative otitis media, Helicobacter pylori infectious disease, alcoholic hepatitis, dyspepsia, pyelonephritis, cholecystitis, endocarditis, neutropenia, gastritis, gastric ulcer, severe acute respiratory syndrome, influenza, Plasmodium falciparum malaria, allergic disease, cystitis, alcoholic liver disease, bronchitis, Clostridium infectious disease